Frost & Sullivan Recognizes Cytomedix for its Pioneering System that Supports the Emerging Regenerative Therapies Market

MOUNTAIN VIEW, Calif., March 6, 2013 /PRNewswire/ --Based on its recent analysis of the regenerative therapies market, Frost & Sullivan recognizes Cytomedix, Inc. with the 2012 North American Frost & Sullivan New Product Innovation Award for its Angel concentrated platelet-rich plasma (cPRP) system that takes significant strides forward for the emerging tissue regeneration applications market. This highly efficient and innovative platelet concentration system is capable of having a far-reaching effect on a large number of orthopedic procedures.

The idea behind applying platelet-rich plasma to wounds is to use the patient's own natural healing process to re-establish equilibrium in the wound environment and alter a non-healing wound or injury to one that heals naturally. However, the development of commercially viable solutions has proven to be a challenge until now. Mounting supportive clinical evidence has Cytomedix poised to deliver on the growing market need.

The Angel cPRP system recently received FDA 510K clearance to process bone marrow aspirate to produce platelet concentrates. This is the second indication it has received clearance for; the first was for whole blood processing. Most PRP systems are open systems, making them susceptible to contamination. The Angel cPRP system is a closed system, and its disposable processing set is pre-sterilized. This helps maintain an aseptic environment for injectable and surgical indications.

The most unique feature of Cytomedix's offering is its flexible therapeutic output. It has a sophisticated computer algorithm that allows physicians to modify red cell count and the corresponding white cell count, as well as reduce neutrophils and granulocytes, according to their clinical preference. This ability to adapt the platelet formulations gives physicians the added freedom to tailor their treatment method.

"With an evolving marketplace, where key opinion leaders are regularly using, researching, publishing and presenting on advances in treatment methodologies, physicians want the flexibility to experiment with different formulations," noted Frost & Sullivan Research Analyst Aarti Shetty. "The Angel cPRP system allows physicians to generate customized platelet concentrates at the point of care by adjusting the concentration and volume levels for different indications from spinal surgery to knee replacement."

Another potential area of application for Angel cPRP is in controlling inflammation and alleviating pain. For instance, the options for a patient with a sports trauma injury can range between a temporary solution such as hyaluronic acid and corticosteroids to major surgery, like total joint replacement. Angel cPRP has the ability to fit in between these large extremes as an alternative solution. This application can have far-reaching effects and will provide much-needed help to thousands of patients in the future.

With many physicians already using the Angel cPRP system, Cytomedix is carefully analyzing all the data from the current usage to design appropriate clinical trials for procedure-specific formulations. Products such as these will have revolutionary effects on the regenerative technologies market.

"Currently, Angel cPRP is used with non-bioactive materials such as bone graft substitutes to create a biologically active environment for bone growth," observed Shetty. "This represents a huge market, and Angel cPRP shows great potential for excellent penetration in this viable market. The value that can be derived from a heterogeneous population of cells is far greater than that which can be derived from single cells like some bone graft products."

Going forward, Frost & Sullivan expects to see more physicians and surgeons adopting Angel cPRP and its formulations as the market moves toward more personalized medicine. In recognition of its valuable potential, Cytomedix is the worthy recipient of the 2012 Frost & Sullivan New Product Innovation Award in the regenerative therapies market.

Each year, Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leveraging leading-edge technologies. The award recognizes the value-added features/benefits of the product and the increased ROI it offers customers, which, in turn, increases customer acquisition and overall market penetration potential.

Go here to read the rest:
Frost & Sullivan Recognizes Cytomedix for its Pioneering System that Supports the Emerging Regenerative Therapies Market